Evaluation in pig of an intestinal administration device for oral peptide delivery – ScienceDirect.com
Evaluation in pig of an intestinal administration device for oral peptide delivery ScienceDirect.com
The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions.
This human clinical study examined nicotinamide mononucleotide (NMN) as a potential intervention for anti-aging, longevity, and chronic disease management by investigating its effects on cellular metabolism and age-related conditions. The research found that NMN demonstrated effects on NAD+ metabolism pathways associated with aging processes and chronic disease states. This evidence is classified as human clinical research.
“Drug-Carrier” Synergy Therapy for Amyloid-β Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly.
Researchers investigated a biomimetic lipid nanocomposite delivery system combining methylene blue (the active agent) with a carrier component designed to address two hallmarks of Alzheimer’s disease pathology: amyloid-β accumulation and tau phosphorylation (in vitro and animal model studies). The nanocomposite demonstrated enhanced clearance of amyloid-β and reduced tau phosphorylation compared to methylene blue alone, suggesting synergistic effects from the drug-carrier combination. **Evidence level: Preclinical (in vitro and animal model).**
A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.
Researchers developed a double-network hydrogel designed to deliver KPV (a tripeptide derived from α-melanocyte-stimulating hormone) to the colon in an animal model of inflammatory bowel disease, demonstrating that the hydrogel improved markers of mucosal barrier function and reduced inflammation in inflamed colon tissue. The hydrogel formulation was engineered to provide sustained KPV release and enhanced adhesion to the intestinal mucosa compared to free KPV alone. **Evidence level: Animal model**
A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Read Post »
Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns.
This review article examined nicotinamide mononucleotide (NMN) as a potential anti-aging intervention, evaluating both its proposed benefits and safety profile across available evidence. The authors identified promises in preclinical models and limited human data regarding metabolic and cardiovascular effects, while also highlighting gaps in long-term safety data and regulatory oversight for NMN as a commercial health product. This is a **review article** synthesizing existing literature rather than original human clinical research.
Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.
This human clinical study describes the design and dose selection rationale for a Phase 3 randomized controlled trial of hydromethylthionine mesylate (a methylene blue derivative), an oral tau aggregation inhibitor being investigated for Alzheimer’s disease treatment. Researchers selected a 16 mg/day dose based on prior pharmacokinetic, safety, and efficacy data from earlier phase trials, with the goal of inhibiting tau protein aggregation while maintaining tolerability. The article presents the scientific basis and trial design rather than reporting primary efficacy outcomes from the Phase 3 trial itself.
Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats.
This animal model study evaluated a self-cross-linked hydrogel delivery system combining cysteamine-grafted γ-polyglutamic acid with the tripeptide KPV in rats with TNBS-induced ulcerative colitis. The hydrogel formulation demonstrated improved stability of the KPV tripeptide and showed alleviating effects on colitis markers in the rat model. This represents preclinical research requiring further development before clinical translation.
Treatment of Kleine-Levin Syndrome With Intranasal Photobiomodulation and Methylene Blue.
This human clinical study describes the treatment of Kleine-Levin Syndrome (a rare condition characterized by recurrent episodes of hypersomnia and behavioral changes) using intranasal photobiomodulation combined with methylene blue in individual patient cases. The report documents patient responses to this combined intervention approach, though specific efficacy data and outcome measures are not detailed in the provided information. As a human clinical case report or small series, this represents lower-level evidence compared to randomized controlled trials.
Found Technology to Overcome Poor Absorption Drawback of ‘Peptide’ Drugs – 아시아경제
Found Technology to Overcome Poor Absorption Drawback of ‘Peptide’ Drugs 아시아경제
Found Technology to Overcome Poor Absorption Drawback of ‘Peptide’ Drugs – 아시아경제 Read Post »
Methylene blue and photobiomodulation recover cognitive impairment in hepatic encephalopathy through different effects on cytochrome c-oxidase.
Researchers investigated how methylene blue and photobiomodulation (light therapy) each improved cognitive function in an animal model of hepatic encephalopathy by examining their effects on cytochrome c-oxidase, a key enzyme in cellular energy production. Both treatments restored cognitive performance in affected animals, but through distinct mechanisms—methylene blue directly enhanced cytochrome c-oxidase activity while photobiomodulation worked through different pathways affecting the same enzyme. This animal model study provides mechanistic insight into how these interventions may address the mitochondrial dysfunction underlying cognitive impairment in hepatic encephalopathy.
Methylene blue reduces incidence of early postoperative cognitive disorders in elderly patients undergoing major non-cardiac surgery: An open-label randomized controlled clinical trial.
This open-label randomized controlled clinical trial (human clinical evidence) investigated whether methylene blue could reduce early postoperative cognitive dysfunction (POCD) in elderly patients undergoing major non-cardiac surgery. The study found that methylene blue treatment reduced the incidence of early POCD in this patient population compared to control. This represents direct clinical evidence from a human trial, though the open-label design (where participants and researchers knew treatment assignment) represents a moderate strength of evidence compared to blinded trials.
Tripeptide/Hexapeptide Topical in Esthetics: Evidence behind the Skincare Formulation.
This review article examined the evidence supporting the use of tripeptide and hexapeptide formulations, particularly GHK-Cu, in topical skincare products for esthetic applications (evidence level: review of clinical and in vitro studies). The review synthesized existing research on how these peptides function in skin formulations, including their purported mechanisms related to collagen production and skin appearance. The article provides an overview of the scientific basis behind peptide-containing skincare products used in esthetic practice.
Tripeptide/Hexapeptide Topical in Esthetics: Evidence behind the Skincare Formulation. Read Post »